Skip to Main Content

Paper Details

Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma.
Sci Transl Med
45
2018
3D drug, MB, MB subtypes groups, MB subtypes groups 3, Medulloblastoma, cancers, digoxin, groups 3 and 4 MB, groups 3 and 4 medulloblastoma, heart failure, human, humans, malignant brain tumor, orthotopic patient-derived xenograft (PDX) models, patient
Author NameAffiliation
Frank K BraunPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Lin QiPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Huiyuan ZhangPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Holly LindsayPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Holly LindsayBaylor College of Medicine
Holly LindsayPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Holly LindsayBaylor College of Medicine
Sibo ZhaoPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Sibo ZhaoBaylor College of Medicine
Patricia BaxterPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Patricia BaxterBaylor College of Medicine
Xiao-Nan LiPreclinical Neuro-Oncology Research Program, Baylor College of Medicine
Xiao-Nan LiBaylor College of Medicine
Ching C LauBaylor College of Medicine
Ching C LauBaylor College of Medicine
Stephen T C WongHouston Methodist Research Institute and Cancer Center
  • 1 - 16

Datasets

Release 1.2